FibroGen, Inc. – LSE:0IL8.L
FibroGen stock price today
FibroGen stock price monthly change
FibroGen stock price quarterly change
FibroGen stock price yearly change
FibroGen key metrics
Market Cap | 41.52M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -2.44 |
Revenue | 167.49M |
EBITDA | -214.53M |
Income | -240.46M |
Revenue Q/Q | 54.59% |
Revenue Y/Y | 44.30% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -128.09% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFibroGen stock price history
FibroGen stock forecast
FibroGen financial statements
| Jun 2023 | 44.31M | -87.68M | -197.84% |
|---|---|---|---|
| Sep 2023 | 40.13M | -63.61M | -158.51% |
| Dec 2023 | 27.13M | -56.23M | -207.21% |
| Mar 2024 | 55.90M | -32.93M | -58.91% |
| Sep 2025 | 49.14M | 22.70M | 46.19% |
|---|---|---|---|
| Oct 2025 | 36.51M | 4.94M | 13.55% |
| Dec 2025 | 37.02M | 5.93M | 16.04% |
| Mar 2026 | 50.01M | 26.08M | 52.15% |
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 | 2.61% |
| Jun 2023 | 515127000 | 575.43M | 111.71% |
|---|---|---|---|
| Sep 2023 | 460426000 | 575.62M | 125.02% |
| Dec 2023 | 423529000 | 585.72M | 138.3% |
| Mar 2024 | 365868000 | 552.02M | 150.88% |
| Jun 2023 | -110.57M | -14.28M | 91.53M |
|---|---|---|---|
| Sep 2023 | -84.53M | 54.21M | -22K |
| Dec 2023 | -18.32M | 10.24M | -246K |
| Mar 2024 | -59.28M | 51.27M | -165K |
FibroGen alternative data
| Aug 2023 | 592 |
|---|---|
| Sep 2023 | 592 |
| Oct 2023 | 592 |
| Nov 2023 | 592 |
| Dec 2023 | 592 |
| Jan 2024 | 592 |
| Feb 2024 | 592 |
| Mar 2024 | 486 |
| Apr 2024 | 486 |
| May 2024 | 486 |
| Jun 2024 | 486 |
| Jul 2024 | 486 |
FibroGen other data
| Patent |
|---|
Grant Filling date: 6 Dec 2016 Issue date: 12 Apr 2022 |
Grant Filling date: 13 Mar 2020 Issue date: 25 Jan 2022 |
Application METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE Filling date: 5 Aug 2021 Issue date: 2 Dec 2021 |
Application Filling date: 30 Mar 2021 Issue date: 30 Sep 2021 |
Application Filling date: 8 Sep 2020 Issue date: 29 Jul 2021 |
Application Filling date: 23 Dec 2020 Issue date: 22 Apr 2021 |
Application Filling date: 23 Dec 2020 Issue date: 15 Apr 2021 |
Application Filling date: 13 Mar 2020 Issue date: 4 Mar 2021 |
Grant Filling date: 30 Jan 2018 Issue date: 23 Feb 2021 |
Grant Filling date: 27 Apr 2017 Issue date: 19 Jan 2021 |
| Insider | Compensation |
|---|---|
| Dr. K. Peony Yu (1962) Chief Medical Officer | $926,210 |
| Dr. Elias Kouchakji (1956) Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance | $863,190 |
| Mr. Pat Cotroneo (1964) Chief Financial Officer | $773,570 |
| Mr. James A. Schoeneck (1958) Chairman | $751,630 |
Ms. Christine L. Chung (1968) Senior Vice President of China Operations | $701,090 |
| Mr. Enrique A. Conterno Chief Executive Officer & Director | |
Ms. Karen L. Bergman Vice President of Investor Relations & Corporation Communications | |
Dr. Michael J. Martinelli Senior Vice President of Technical Devel. | |
Dr. Barry A. Berkowitz Founder | |
Dr. Percy Carter M.B.A., Ph.D. Chief Scientific Officer |
-
What's the price of FibroGen stock today?
One share of FibroGen stock can currently be purchased for approximately $52.55.
-
When is FibroGen's next earnings date?
Unfortunately, FibroGen's (0IL8.L) next earnings date is currently unknown.
-
Does FibroGen pay dividends?
No, FibroGen does not pay dividends.
-
How much money does FibroGen make?
FibroGen has a market capitalization of 41.52M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.99% to 147.75M US dollars.
-
What is FibroGen's stock symbol?
FibroGen, Inc. is traded on the LSE under the ticker symbol "0IL8.L".
-
What is FibroGen's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of FibroGen?
Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are FibroGen's key executives?
FibroGen's management team includes the following people:
- Dr. K. Peony Yu Chief Medical Officer(age: 63, pay: $926,210)
- Dr. Elias Kouchakji Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance(age: 69, pay: $863,190)
- Mr. Pat Cotroneo Chief Financial Officer(age: 61, pay: $773,570)
- Mr. James A. Schoeneck Chairman(age: 67, pay: $751,630)
- Ms. Christine L. Chung Senior Vice President of China Operations(age: 57, pay: $701,090)
- Mr. Enrique A. Conterno Chief Executive Officer & Director
- Ms. Karen L. Bergman Vice President of Investor Relations & Corporation Communications
- Dr. Michael J. Martinelli Senior Vice President of Technical Devel.
- Dr. Barry A. Berkowitz Founder
- Dr. Percy Carter M.B.A., Ph.D. Chief Scientific Officer
-
Is FibroGen founder-led company?
Yes, FibroGen is a company led by its founder Dr. Barry A. Berkowitz.
-
How many employees does FibroGen have?
As Jul 2024, FibroGen employs 486 workers.
-
When FibroGen went public?
FibroGen, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is FibroGen's official website?
The official website for FibroGen is fibrogen.com.
-
Where are FibroGen's headquarters?
FibroGen is headquartered at 409 Illinois Street, San Francisco, CA.
-
How can i contact FibroGen?
FibroGen's mailing address is 409 Illinois Street, San Francisco, CA and company can be reached via phone at +41 59781200.
FibroGen company profile:
FibroGen, Inc.
fibrogen.comLSE
486
Medical - Pharmaceuticals
Healthcare
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
San Francisco, CA 94158
:
ISIN: US31572Q8087
:
